Skip to main content

Caffeine Citrate Therapy for Apnea of Prematurity

Buy Article:

$25.00 plus tax (Refund Policy)


CAFFEINE IS A DRUG commonly used in the neonatal intensive care unit. Given its frequent use, providers need to be well informed of the drug, its indications, mechanism of action, and pharmacokinetics. Caffeine has an important history of skeptics and variable practice preference, ultimately leading to fairly new evidence supporting its pharmacologic attributes for treatment of apnea of prematurity (AOP). Caffeine is also used to stimulate preextubation respiratory drive in the nursery and following anesthesia. The purpose of this column is to review the history of methylxanthine therapy as a treatment for AOP, examine the benefits of caffeine citrate (Cafcit®) as the methylxanthine of choice, including the pharmacology and pharmacokinetics of the drug, and review the current evidence-based practice for the use of Cafcit® in the treatment of AOP.

Document Type: Research Article


Publication date: November 1, 2011

More about this publication?

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more